COMPARISON OF THE EFFICACY AND SAFETY OF EVEROLIMUS-, SIROLIMUS- AND ZOTAROLIMUS-ELUTING STENTS IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION  by Jang, Jae-Sik et al.
    
  i2 SUMMIT   
E1701
JACC April 5, 2011
Volume 57, Issue 14
COMPARISON OF THE EFFICACY AND SAFETY OF EVEROLIMUS-, SIROLIMUS- AND ZOTAROLIMUS-
ELUTING STENTS IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION
i2 Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: PCI - DES I
Abstract Category: 16. PCI - DES (clinical/outcomes)
Session-Poster Board Number: 2501-595
Authors: Jae-Sik Jang, Han Young Jin, Young-Wan Jo, Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Dong-Soo Kim, Inje University Busan Paik 
Hospital, Busan, South Korea
Background: Drug-eluting stents (DESs) seem to be non-inferior to bare metal stents in terms of clinical outcomes in patients with ST-segment 
elevation myocardial infarction (STEMI). We compared the efficacy and safety of everolimus-eluting stents (EESs), sirolimus-eluting stents (SESs), and 
zotarolimus-eluting stents (ZESs) in primary intervention for STEMI.
Methods: A total of 354 consecutive patients with STEMI who received EES (n = 100), SES (n = 186), or ZES (n = 68) were analyzed. The primary 
end point was 1-year composite rate of major adverse cardiac events (defined as death, MI, or ischemia-driven target vessel revascularization). 
Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis.
Results: Baseline clinical characteristics were similar between the three groups. In-segment late loss (p = 0.002) and restenosis rate (p = 0.032) 
at 8 months were lowest in the EES group compared to the SES and ZES groups. At 12 months, cumulative incidence rates of primary endpoints in 
the EES, SES, and ZES groups were 8.0%, 13.4%, and 14.7%, respectively (p = 0.313). There were 1 acute (in the ZES group), 2 subacute (1 in the 
SES and 1 in the ZES group), and 2 late (in the SES group) stent thromboses.
Conclusions: The EES showed similar rates of mortality and of major adverse cardiac events, with lower rates of angiographic restenosis for 
patients with STEMI compared with SES and ZES. 
